- Email: [email protected]
5416201 DNAs that code for mouse interleuken 4
PATENT ABSTRACTS
5416195 POLYPEPTIDE DERIVATIVES GRANULOCYTE COLONY STIMULATING FACTOR
291
5416201 OF
Camble Roger; Can Heather; Timms David; Wilkinson Anthony J Macclesfield, UNITED KINGDOM Assigned to Zeneca Limited Derivatives of naturally occurring G-CSF having at least one of the biological properties of naturally occurring G-CSF, and a solution stability of at least 35% at 5 mg/ml are disclosed in which the derivative has at least Cysl7 of the native sequence replaced by a Serl7 residue and Asp27 of the native sequence replaced by a Serl7 residue. Nucleotide sequences coding for part or all of the amino acid sequence of the derivatives of the invention may he incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable proearyotic or euearyotic host cells such as bacteria, yeast or vertebrate cells in culture.
5416197 ANTIBODIES WHICH BIND HUMAN COLLAPSIN Raper Jonathan A; Luo Yuling Wynnewood, PA, UNITED STATES Assigned to Trustees of the University of Pennsylvania Essentially pure human collapsin and its uses are disclosed. An isolated nucleic acid molecule that comprises a nucleotide sequence that is complementary to a nucleotide sequence that encodes a portion of human collapsin is disclosed. Antibodies that specifically bind to human collapsin and that inhibit its activity are disclosed. Methods of inhibiting the activity of collapsin, methods of inducing neurite outgrowth and methods of treating individuals suffering from nerve damage comprising the step of contacting neuronal cells with nucleic acid molecule that comprises a nucleotide sequence that is complementary to a nucleotide sequence that encodes a portion of human collapsin or comprising the step of contacting a neuronal cell with an antibody that specifically binds to human collapsin are disclosed. Methods of identifying compounds that inhibit the activity of human collapsin comprising the steps of contacting a neuronal cell with human collapsin in the presence of a test compound are disclosed.
DNAS THAT CODE FOR MOUSE INTERLEUKEN 4 Honjo Tasuk; Severinson Eva Toyonaka shi, Osaka, SWEDEN Assigned to Honjo Tasuku Mouse IgGl inducing factor and the DNA that codes for the same were isolated by using a novel genetic technique, and their structures determined by the dideoxy chain termination method. The mouse IgG1 inducing factor obtained by the method of this invention has activity to improve immune response in living bodies and are hence useful for the treatment and prevention of infectious diseases, AIDS, functional immunodeficiency and the like. This factor, or part of its amino acid sequence, may also he used for the preparation of antibody against the same. In addition, it is possible to use this factor as a model for the synthesis of other polypeptides having similar structures, and for many other purposes.
5416202 MATERIALS COMPRISING AND METHODS OF PREPARATION AND USE FOR RIBOSOMEINACTIVATING PROTEINS Bernhard Susan L; Better Marc D; Carroll Steve F; Lane Julie A; Lei Shau-Ping Menlo Park, CA, UNITED STATES Assigned to XOMA Corporation The present invention provides purified and isolated polynudeotides encoding Type I ribosome-inactivating proteins (RIPs) such as gelnnin and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a
5416195 POLYPEPTIDE DERIVATIVES GRANULOCYTE COLONY STIMULATING FACTOR
291
5416201 OF
Camble Roger; Can Heather; Timms David; Wilkinson Anthony J Macclesfield, UNITED KINGDOM Assigned to Zeneca Limited Derivatives of naturally occurring G-CSF having at least one of the biological properties of naturally occurring G-CSF, and a solution stability of at least 35% at 5 mg/ml are disclosed in which the derivative has at least Cysl7 of the native sequence replaced by a Serl7 residue and Asp27 of the native sequence replaced by a Serl7 residue. Nucleotide sequences coding for part or all of the amino acid sequence of the derivatives of the invention may he incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable proearyotic or euearyotic host cells such as bacteria, yeast or vertebrate cells in culture.
5416197 ANTIBODIES WHICH BIND HUMAN COLLAPSIN Raper Jonathan A; Luo Yuling Wynnewood, PA, UNITED STATES Assigned to Trustees of the University of Pennsylvania Essentially pure human collapsin and its uses are disclosed. An isolated nucleic acid molecule that comprises a nucleotide sequence that is complementary to a nucleotide sequence that encodes a portion of human collapsin is disclosed. Antibodies that specifically bind to human collapsin and that inhibit its activity are disclosed. Methods of inhibiting the activity of collapsin, methods of inducing neurite outgrowth and methods of treating individuals suffering from nerve damage comprising the step of contacting neuronal cells with nucleic acid molecule that comprises a nucleotide sequence that is complementary to a nucleotide sequence that encodes a portion of human collapsin or comprising the step of contacting a neuronal cell with an antibody that specifically binds to human collapsin are disclosed. Methods of identifying compounds that inhibit the activity of human collapsin comprising the steps of contacting a neuronal cell with human collapsin in the presence of a test compound are disclosed.
DNAS THAT CODE FOR MOUSE INTERLEUKEN 4 Honjo Tasuk; Severinson Eva Toyonaka shi, Osaka, SWEDEN Assigned to Honjo Tasuku Mouse IgGl inducing factor and the DNA that codes for the same were isolated by using a novel genetic technique, and their structures determined by the dideoxy chain termination method. The mouse IgG1 inducing factor obtained by the method of this invention has activity to improve immune response in living bodies and are hence useful for the treatment and prevention of infectious diseases, AIDS, functional immunodeficiency and the like. This factor, or part of its amino acid sequence, may also he used for the preparation of antibody against the same. In addition, it is possible to use this factor as a model for the synthesis of other polypeptides having similar structures, and for many other purposes.
5416202 MATERIALS COMPRISING AND METHODS OF PREPARATION AND USE FOR RIBOSOMEINACTIVATING PROTEINS Bernhard Susan L; Better Marc D; Carroll Steve F; Lane Julie A; Lei Shau-Ping Menlo Park, CA, UNITED STATES Assigned to XOMA Corporation The present invention provides purified and isolated polynudeotides encoding Type I ribosome-inactivating proteins (RIPs) such as gelnnin and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a